FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and can be used to treat a patient with a malignant tumour associated with a WEE1 kinase. To this end, the patient undergoes measurement of the expression level of the PKMYT1 gene in a biological sample containing malignant cells obtained from said patient and in a control sample. Further, it is determined whether expression level of the PKMYT1 gene in said sample from the patient is higher or lower than the expression level in said control sample. Said patient is then selected for treatment with a WEE1 inhibitor if the PKMYT1 level from the patient’s sample is lower than in the control sample. And the patient selected for treatment of a malignant tumour is injected with a WEE1 inhibitor. Also disclosed is a method for treating a patient with a malignant tumour associated with a WEE1 kinase, where the patients are characterised by low expression levels of PKMYT1.
EFFECT: group of inventions provides treatment of a malignant tumour in patients with low expression levels of PKMYT1.
13 cl, 20 dwg, 9 ex
Title | Year | Author | Number |
---|---|---|---|
THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR BLADDER CANCER | 2015 |
|
RU2739942C2 |
BIOMARKERS PREDICTING A THERAPEUTIC RESPONSE TO THERAPY WITH A CHIMERIC ANTIGEN RECEPTOR, AND USE THEREOF | 2015 |
|
RU2743657C2 |
DIAGNOSTIC MARKERS | 2012 |
|
RU2614254C2 |
METHODS FOR TREATMENT OF MALIGNANT TUMORS, USING ATR INHIBITOR | 2018 |
|
RU2813966C2 |
TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
MARKERS ASSOCIATED WITH WNT INHIBITORS | 2014 |
|
RU2663701C2 |
BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS | 2014 |
|
RU2820869C1 |
BIOMARKERS AND METHODS OF TREATING ASSOCIATED WITH PD-1 AND PD-L1 CONDITIONS | 2014 |
|
RU2701378C2 |
COMBINATION OF CHEKPOINT-KINASE 1 INHIBITORS AND WEE 1 KINASE INHIBITORS | 2011 |
|
RU2627841C2 |
METHOD OF USING AXL AS MARKER OF EPITHELIAL-MESENCHYMAL TRANSITION | 2010 |
|
RU2586493C2 |
Authors
Dates
2018-07-05—Published
2013-11-22—Filed